TY - JOUR
T1 - Associations of circulating GDF15 with combined cognitive frailty and depression in older adults of the MARK-AGE study
AU - Kochlik, Bastian
AU - Herpich, Catrin
AU - Moreno-Villanueva, María
AU - Klaus, Susanne
AU - Müller-Werdan, Ursula
AU - Weinberger, Birgit
AU - Fiegl, Simone
AU - Toussaint, Olivier
AU - Debacq-Chainiaux, Florence
AU - Schön, Christiane
AU - Bernhard, Jürgen
AU - Breusing, Nicolle
AU - Gonos, Efstathios S.
AU - Franceschi, Claudio
AU - Capri, Miriam
AU - Sikora, Ewa
AU - Hervonen, Antti
AU - Hurme, Mikko
AU - Slagboom, P. Eline
AU - Dollé, Martijn E.T.
AU - Jansen, Eugene
AU - Grune, Tilman
AU - Bürkle, Alexander
AU - Norman, Kristina
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/9/16
Y1 - 2023/9/16
N2 - Growth differentiation factor-15 (GDF15) might be involved in the development of cognitive frailty and depression. Therefore, we evaluated cross-sectional associations of plasma GDF15 with combined cognitive-frailty-and-depression in older (i.e. ≥ 55 years) and younger adults of the MARK-AGE study. In the present work, samples and data of MARK-AGE (“European study to establish bioMARKers of human AGEing“) participants (N = 2736) were analyzed. Cognitive frailty was determined by the global cognitive functioning score (GCF) and depression by the Self-Rating Depression Scale (SDS score). Adults were classified into three groups: (I) neither-cognitive-frailty-nor-depression, (II) either-cognitive-frailty-or-depression or (III) both-cognitive-frailty-and-depression. Cross-sectional associations were determined by unadjusted and by age, BMI, sex, comorbidities and hsCRP-adjusted linear and logistic regression analyses. Cognitive frailty, depression, age and GDF15 were significantly related within the whole study sample. High GDF15 levels were significantly associated with both-cognitive-frailty-and-depression (adjusted β = 0.177 [0.044 – 0.310], p = 0.009), and with low GCF scores and high SDS scores. High GDF15 concentrations and quartiles were significantly associated with higher odds to have both-cognitive-frailty-and-depression (adjusted odds ratio = 2.353 [1.267 – 4.372], p = 0.007; and adjusted odds ratio = 1.414 [1.025 – 1.951], p = 0.035, respectively) independent of age, BMI, sex, comorbidities and hsCRP. These associations remained significant when evaluating older adults. We conclude that plasma GDF15 concentrations are significantly associated with combined cognitive-frailty-and-depression status and, with cognitive frailty and depressive symptoms separately in old as well as young community-dwelling adults.
AB - Growth differentiation factor-15 (GDF15) might be involved in the development of cognitive frailty and depression. Therefore, we evaluated cross-sectional associations of plasma GDF15 with combined cognitive-frailty-and-depression in older (i.e. ≥ 55 years) and younger adults of the MARK-AGE study. In the present work, samples and data of MARK-AGE (“European study to establish bioMARKers of human AGEing“) participants (N = 2736) were analyzed. Cognitive frailty was determined by the global cognitive functioning score (GCF) and depression by the Self-Rating Depression Scale (SDS score). Adults were classified into three groups: (I) neither-cognitive-frailty-nor-depression, (II) either-cognitive-frailty-or-depression or (III) both-cognitive-frailty-and-depression. Cross-sectional associations were determined by unadjusted and by age, BMI, sex, comorbidities and hsCRP-adjusted linear and logistic regression analyses. Cognitive frailty, depression, age and GDF15 were significantly related within the whole study sample. High GDF15 levels were significantly associated with both-cognitive-frailty-and-depression (adjusted β = 0.177 [0.044 – 0.310], p = 0.009), and with low GCF scores and high SDS scores. High GDF15 concentrations and quartiles were significantly associated with higher odds to have both-cognitive-frailty-and-depression (adjusted odds ratio = 2.353 [1.267 – 4.372], p = 0.007; and adjusted odds ratio = 1.414 [1.025 – 1.951], p = 0.035, respectively) independent of age, BMI, sex, comorbidities and hsCRP. These associations remained significant when evaluating older adults. We conclude that plasma GDF15 concentrations are significantly associated with combined cognitive-frailty-and-depression status and, with cognitive frailty and depressive symptoms separately in old as well as young community-dwelling adults.
KW - Aging
KW - Biomarker
KW - Cognitive frailty
KW - Depression
KW - GDF15
UR - http://www.scopus.com/inward/record.url?scp=85171256325&partnerID=8YFLogxK
U2 - 10.1007/s11357-023-00902-6
DO - 10.1007/s11357-023-00902-6
M3 - Article
AN - SCOPUS:85171256325
SN - 2509-2715
VL - 46
SP - 1657
EP - 1669
JO - GeroScience
JF - GeroScience
IS - 2
ER -